中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1677-1682

Mechanism of action of 2-acylglycerol O-acyltransferase 2 in metabolic associated fatty liver disease and related targeted therapies

DOI: 10.12449/JCH260726
  • 1.

    The First Clinical Medical College of Lanzhou University，Lanzhou 730000，China

  • 2.

    Department of Gastroenterology，Gansu Province Clinical Research Center for Digestive Diseases，The First Hospital of Lanzhou University，Lanzhou 730000，China

Research funding:

Central Government Guiding Local Scientific and Technological Development Fund (25ZYJA02)

More Information
  • Corresponding author: Ji Rui， jir@lzu.edu.cn （ORCID： 0000-0001-9011-2222）
  • Received Date: 2025-10-23
  • Accepted Date: 2025-11-25
  • Published Date: 2026-07-25
    Abstract
  • Metabolic associated fatty liver disease （MAFLD） has become one of the most prevalent chronic liver diseases worldwide， with the core pathological feature of pathological accumulation of triglycerides in hepatocytes， and as a key rate-limiting enzyme for triglyceride synthesis in the liver， 2-acylglycerol O-acyltransferase 2 （DGAT2） plays a central role in this process. Cell and animal model studies have confirmed that inhibition of DGAT2 can effectively alleviate hepatic steatosis and delay disease progression， and subsequent clinical trials have also shown the potential clinical application value in the treatment of MAFLD. This article systematically reviews the mechanism of action of DGAT2 in the development and progression of MAFLD and comprehensively summarizes the therapeutic strategies targeting DGAT2， including the advances in both monotherapy and drug combinations， in order to provide new ideas for individualized treatment of MAFLD patients.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic)fatty liver disease(Version 2024)[J]. J Prac Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.

    中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.
    [2]
    Lin Z, Zhang R X, Ren S H, et al. Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years[J]. Prev Med Rep, 2025, 59: 103248. DOI: 10.1016/j.pmedr.2025.103248.
    [3]
    Rong S X, Xia M F, Vale G, et al. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER[J]. Cell Metab, 2024, 36( 3): 617- 629.e7. DOI: 10.1016/j.cmet.2024.01.011.
    [4]
    Amin N B, Saxena A R, Somayaji V, et al. Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: Potential therapeutic implications of pharmacology[J]. Clin Ther, 2023, 45( 1): 55- 70. DOI: 10.1016/j.clinthera.2022.12.008.
    [5]
    Chen G Q, Harwood J L, Lemieux M J, et al. Acyl-CoA: Diacylglycerol acyltransferase: Properties, physiological roles, metabolic engineering and intentional control[J]. Prog Lipid Res, 2022, 88: 101181. DOI: 10.1016/j.plipres.2022.101181.
    [6]
    Malis Y, Armoza-Eilat S, Nevo-Yassaf I, et al. Rab1b facilitates lipid droplet growth by ER-to-lipid droplet targeting of DGAT2[J]. Sci Adv, 2024, 10( 22): eade7753. DOI: 10.1126/sciadv.ade7753.
    [7]
    Luo X T, Yuan Y X, Ma X C, et al. Diacylglycerol O-acyltransferase 2, a novel target of flavivirus NS2B3 protease, promotes zika virus replication by regulating lipid droplet formation[J]. Research(Wash D C), 2024, 7: 0511. DOI: 10.34133/research.0511.
    [8]
    Yenilmez B, Wetoska N, Kelly M, et al. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis[J]. Mol Ther, 2022, 30( 3): 1329- 1342. DOI: 10.1016/j.ymthe.2021.11.007.
    [9]
    Wang H, Airola M V, Reue K. How lipid droplets“TAG” along: Glycerolipid synthetic enzymes and lipid storage[J]. Biochim Biophys Acta BBA Mol Cell Biol Lipds, 2017, 1862( 10): 1131- 1145. DOI: 10.1016/j.bbalip.2017.06.010.
    [10]
    Kim G, Lee J, Ha J, et al. Endoplasmic reticulum stress and its impact on adipogenesis: Molecular mechanisms implicated[J]. Nutrients, 2023, 15( 24): 5082. DOI: 10.3390/nu15245082.
    [11]
    Bhatt-Wessel B, Jordan T W, Miller J H, et al. Role of DGAT enzymes in triacylglycerol metabolism[J]. Arch Biochem Biophys, 2018, 655: 1- 11. DOI: 10.1016/j.abb.2018.08.001.
    [12]
    Rauff B, Alzahrani B, Chudhary S A, et al. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: A genetic association study[J]. BMC Gastroenterol, 2022, 22( 1): 401. DOI: 10.1186/s12876-022-02469-6.
    [13]
    Jornayvaz F R, Birkenfeld A L, Jurczak M J, et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2[J]. Proc Natl Acad Sci U S A, 2011, 108( 14): 5748- 5752. DOI: 10.1073/pnas.1103451108.
    [14]
    Loomba R, Morgan E, Yousefi K, et al. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis(ION224-CS2): Results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2025, 406( 10505): 821- 831. DOI: 10.1016/S0140-6736(25)00979-1.
    [15]
    Farese R V Jr, Zechner R, Newgard C B, et al. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance[J]. Cell Metab, 2012, 15( 5): 570- 573. DOI: 10.1016/j.cmet.2012.03.004.
    [16]
    Lyu K, Zhang Y, Zhang D Y, et al. A membrane-bound diacylglycerol species induces PKCϵ-mediated hepatic insulin resistance[J]. Cell Metab, 2020, 32( 4): 654- 664. e 5. DOI: 10.1016/j.cmet.2020.08.001.
    [17]
    Longo M, Paolini E, di Benedetto P, et al. DGAT1 and DGAT2 inhibitors for metabolic dysfunction-associated steatotic liver disease(MASLD) management: Benefits for their single or combined application[J]. Int J Mol Sci, 2024, 25( 16): 9074. DOI: 10.3390/ijms25169074.
    [18]
    Luo Z Z, Huang Y X, Yong K, et al. Gut microbiota regulates hepatic ketogenesis and lipid accumulation in ketogenic diet-induced hyperketonemia by disrupting bile acid metabolism[J]. Gut Microbes, 2025, 17( 1): 2496437. DOI: 10.1080/19490976.2025.2496437.
    [19]
    Chen Y H, Chiu C C, Hung S W, et al. Gnotobiotic mice inoculated with Firmicutes, but not Bacteroidetes, deteriorate nonalcoholic fatty liver disease severity by modulating hepatic lipid metabolism[J]. Nutr Res, 2019, 69: 20- 29. DOI: 10.1016/j.nutres.2019.07.001.
    [20]
    Mohiuddin M S, Neha N T, Mahir J U K, et al. Metabolic dysfunction associated fatty liver disease and type 2 diabetes: Pathophysiological links, epidemiological trends, and clinical implications[J]. Front Endocrinol, 2025, 16: 1669478. DOI: 10.3389/fendo.2025.1669478.
    [21]
    Liu W F, Chen S Z, Yang C Z, et al. Elevated high-density lipoprotein triglycerides increase atherosclerotic risk[J]. J Lipid Res, 2025, 66( 5): 100791. DOI: 10.1016/j.jlr.2025.100791.
    [22]
    Kargbo R B. Treatment of metabolic disorders using novel DGAT2 inhibitors: Pyrazolopyridine and triazolopyridine derivatives[J]. ACS Med Chem Lett, 2024, 15( 8): 1199- 1200. DOI: 10.1021/acsmedchemlett.4c00329.
    [23]
    Loomba R, Morgan E, Watts L, et al. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: A multicentre, double-blind, randomised, placebo-controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2020, 5( 9): 829- 838. DOI: 10.1016/S2468-1253(20)30186-2.
    [24]
    Futatsugi K, Kung D W, Orr S T, et al. Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2(DGAT2)[J]. J Med Chem, 2015, 58( 18): 7173- 7185. DOI: 10.1021/acs.jmedchem.5b01006.
    [25]
    Amin N B, Carvajal-Gonzalez S, Purkal J, et al. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis[J]. Sci Transl Med, 2019, 11( 520): eaav9701. DOI: 10.1126/scitranslmed.aav9701.
    [26]
    Wong V W, Amin N B, Takahashi H, et al. Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis(MIRNA): Results from a phase 2, randomised, double-blind, double-dummy study[J]. Lancet Gastroenterol Hepatol, 2025, 10( 10): 924- 940. DOI: 10.1016/S2468-1253(25)00128-1.
    [27]
    Filipski K J, Edmonds D J, Garnsey M R, et al. Design of next-generation DGAT2 inhibitor PF-07202954 with longer predicted half-life[J]. ACS Med Chem Lett, 2023, 14( 10): 1427- 1433. DOI: 10.1021/acsmedchemlett.3c00330.
    [28]
    Zhu Y W, Cai B S. Mechanisms and therapeutic insights into MASH-associated fibrosis[J]. Trends Endocrinol Metab, 2026, 37( 5): 402- 417. DOI: 10.1016/j.tem.2025.09.004.
    [29]
    Patel P. Treatment landscape of metabolic-dysfunction-associated steatotic liver disease[J]. J Clin Med, 2025, 14( 17): 6060. DOI: 10.3390/jcm14176060.
    [30]
    Calle R A, Amin N B, Carvajal-Gonzalez S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials[J]. Nat Med, 2021, 27( 10): 1836- 1848. DOI: 10.1038/s41591-021-01489-1.
    [31]
    Takemoto K, Fukasaka Y, Yoshimoto R, et al. Diacylglycerol acyltransferase 1/2 inhibition induces dysregulation of fatty acid metabolism and leads to intestinal barrier failure and diarrhea in mice[J]. Physiol Rep, 2020, 8( 15): e14542. DOI: 10.14814/phy2.14542.
    [32]
    Yenilmez B, Harney S, DiMarzio C, et al. Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice[PP/OL]. bioRxiv( 2023-07-05). https://www.biorxiv.org/content/10.1101/2023.07.05.547848v1. DOI: 10.1101/2023.07.05.547848v1
    [33]
    Jamal F, Elshaer A, Odeh N B, et al. Resmetirom in the management of metabolic dysfunction-associated steatotic liver disease and steatohepatitis[J]. Life, 2025, 15( 8): 1306. DOI: 10.3390/life15081306.
    [34]
    Boutari C, Hill M A, Mantzoros C S. Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis[J]. Metabolism, 2026, 174: 156397. DOI: 10.1016/j.metabol.2025.156397.
    [35]
    Sabatini S, Gastaldelli A. Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor[J]. J Hepatol, 2025, 82( 6): 950- 952. DOI: 10.1016/j.jhep.2025.03.003.
    [36]
    Cui X Y, Sun Q H, Wang H Q. Targeting fibroblast growth factor(FGF)-21: A promising strategy for metabolic dysfunction-associated steatotic liver disease treatment[J]. Front Pharmacol, 2025, 16: 1510322. DOI: 10.3389/fphar.2025.1510322.
    [37]
    Li Y Y, Ye L R, Cui Y Z, et al. DGAT2 reduction and lipid dysregulation drive psoriasis development in keratinocyte-specific SPRY1-deficient mice[J]. JCI Insight, 2025, 10( 17): e192507. DOI: 10.1172/jci.insight.192507.
    [38]
    Gluchowski N L, Gabriel K R, Chitraju C, et al. Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: Diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice[J]. Hepatology, 2019, 70( 6): 1972- 1985. DOI: 10.1002/hep.30765.
    [39]
    Lee W H, Kipp Z A, Bates E A, et al. The physiology of MASLD: Molecular pathways between liver and adipose tissues[J]. Clin Sci(Lond), 2025, 139( 18): 1015- 1046. DOI: 10.1042/CS20257571.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (62) PDF downloads(14) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return